Regulatory watch: Outcomes of early health technology assessment dialogues in medicinal product development.
作者信息
Maignen François, Osipenko Leeza, Pinilla-Dominguez Pilar, Crowe Emily
机构信息
The Office of Health Economics Southside, 7th Floor, 105 Victoria Street, London SW1E 6QT, UK.
Centre for Health Technology Evaluation, National Institute for Health and Care Excellence, 10 Spring Gardens, London SW1A 2BU, UK.
出版信息
Nat Rev Drug Discov. 2017 Feb 2;16(2):79. doi: 10.1038/nrd.2016.286.
PMID:28148947
Abstract
摘要
相似文献
1
Regulatory watch: Outcomes of early health technology assessment dialogues in medicinal product development.
Nat Rev Drug Discov. 2017 Feb 2;16(2):79. doi: 10.1038/nrd.2016.286.
2
Patent watch: Australia's highest court decides isolated nucleic acids are not patent eligible.
Nat Rev Drug Discov. 2015 Dec;14(12):813. doi: 10.1038/nrd4790. Epub 2015 Nov 16.
3
Regulatory control in drug design of radiopharmaceuticals in Japan.
Nihon Hoshasen Gijutsu Gakkai Zasshi. 2014 Jan;70(1):73-5.
4
Adaptive licensing and facilitated regulatory pathways: A survey of stakeholder perceptions.
Clin Pharmacol Ther. 2015 Nov;98(5):477-9. doi: 10.1002/cpt.140. Epub 2015 Jun 30.
5
Innovative medicines: new regulatory procedures for the third millennium.
Expert Opin Biol Ther. 2015;15 Suppl 1:S5-8. doi: 10.1517/14712598.2015.1026322. Epub 2015 Mar 16.
6
New EU regulation on health technology assessment of cancer medicines.
Lancet Oncol. 2022 Feb;23(2):e58. doi: 10.1016/S1470-2045(22)00008-0.
7
China's drug innovation and policy environment.
Drug Discov Today. 2011 Jan;16(1-2):1-3. doi: 10.1016/j.drudis.2010.05.004. Epub 2010 May 31.
8
Commentary: innovation policy for a new era.
J Law Med Ethics. 2009 Summer;37(2):264-8. doi: 10.1111/j.1748-720X.2009.00370.x.
9
Regulatory science and the role of the regulator in biomedical innovation.
Clin Pharmacol Ther. 2012 Mar;91(3):347-52. doi: 10.1038/clpt.2011.352.
10
Information on new drugs at market entry: retrospective analysis of health technology assessment reports versus regulatory reports, journal publications, and registry reports.
BMJ. 2015 Feb 26;350:h796. doi: 10.1136/bmj.h796.
引用本文的文献
1
Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia.
Appl Health Econ Health Policy. 2019 Dec;17(6):883-893. doi: 10.1007/s40258-019-00496-1.
Zotero 插件